{
    "clinical_study": {
        "@rank": "92389", 
        "arm_group": [
            {
                "arm_group_label": "IPDI Qvar", 
                "description": "ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate"
            }, 
            {
                "arm_group_label": "IPDI FP", 
                "description": "ICS initiation as fluticasone propionate"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary aim of this study was to compare the absolute and relative effectiveness of\n      asthma management in paediatric patients in the UK on inhaled corticosteroid (ICS)\n      maintenance therapy as extra-fine HFA-BDP (Qvar\u00ae) pressurised metered dose inhaler (pMDI)\n      compared with fluticasone propionate (FP) pMDI."
        }, 
        "brief_title": "Qvar vs FP in Pediatrics", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "Comparison of asthma control with extrafine-particle hydrofluoroalkane-beclometasone (EF\n      HFA-BDP) vs fluticasone propionate (FP) in paediatric patients (5-11year olds). Patients\n      identified from the General Practice Research Database (GPRD) and the Optimum Patient Care\n      Research Database (OPCRD). Two analyses were conducted:\n\n        1. Comparison of outcomes achieved by EF HFA-BDP and FP in 5-6year old patients with those\n           achieved in 7-11yr old patients.\n\n        2. Comparison of outcomes achieved by EF HFA-BDP used with or without a spacer to those\n           achieved by standard particle fluticasone propionate (FP) used with a spacer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged: 5-11 years\n\n          2. Evidence of asthma (diagnostic code and/or current asthma therapy);\n\n          3. Have at least one year of up-to-standard (UTS) baseline data (during which the\n             step-up to FP/SAL occurred) and at least one year of UTS outcome data (following the\n             IPD).\n\n        Exclusion Criteria:\n\n          1. Had any chronic respiratory disease, except asthma, at any time; and/or\n\n          2. Patients on maintenance oral steroids during baseline year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "5 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Asthma patients who initiate ICS therapy as one of:\n\n        HFA-BDP pMDI FP pMDI"
            }
        }, 
        "enrollment": {
            "#text": "2654", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877954", 
            "org_study_id": "R02511"
        }, 
        "intervention": [
            {
                "arm_group_label": "IPDI Qvar", 
                "intervention_name": "Extra-fine hydrofluoroalkane beclometasone dipropionate", 
                "intervention_type": "Drug", 
                "other_name": "Qvar\u00ae"
            }, 
            {
                "arm_group_label": "IPDI FP", 
                "intervention_name": "Fluticasone propionate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluticasone", 
                "Beclomethasone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hydrofluoroalkane beclomethasone", 
            "fluticasone", 
            "paediatrics", 
            "real-life", 
            "observational", 
            "primary care"
        ], 
        "lastchanged_date": "June 13, 2013", 
        "link": [
            {
                "url": "http://www.optimumpatientcare.org/Html_Docs/OPCRD.html"
            }, 
            {
                "url": "http://www.cprd.com/intro.asp"
            }
        ], 
        "number_of_groups": "2", 
        "official_title": "Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients \u2014 a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population", 
        "overall_official": {
            "affiliation": "Research in real life", 
            "last_name": "David Price", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Defined as the absence of the following during the one-year outcome period:\nAsthma-related:\nHospital attendance or admission, OR\nA&E attendance, OR\nOut of hours attendance, OR\nOut-patient department attendance\nGP consultations for lower respiratory tract infection\nPrescriptions for acute courses of oral steroids .", 
                "measure": "Proxy risk domain asthma control", 
                "safety_issue": "No", 
                "time_frame": "One year outcome period"
            }, 
            {
                "description": "Where exacerbations are defined as an occurrence of:\nDefined as an occurrence of:\nAsthma related:\nHospital admission, OR\nA&E attendance, OR\nUse of acute oral steroids.", 
                "measure": "Asthma exacerbation rate ratio", 
                "safety_issue": "No", 
                "time_frame": "One year outcome period"
            }
        ], 
        "reference": [
            {
                "PMID": "16379614", 
                "citation": "Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med. 2005 Winter;18(4):379-85."
            }, 
            {
                "PMID": "9877489", 
                "citation": "Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998 Dec;12(6):1346-53."
            }, 
            {
                "PMID": "11866004", 
                "citation": "Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002 Feb;19(2):246-51."
            }, 
            {
                "PMID": "1750017", 
                "citation": "Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991 Oct;46(10):712-6."
            }, 
            {
                "PMID": "6440305", 
                "citation": "Newman SP, Millar AB, Lennard-Jones TR, Mor\u00e9n F, Clarke SW. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax. 1984 Dec;39(12):935-41."
            }, 
            {
                "PMID": "19513494", 
                "citation": "Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J. 2009 Dec;18(4):243-9. Review."
            }, 
            {
                "PMID": "17140424", 
                "citation": "Price D, Thomas M. Breaking new ground: challenging existing asthma guidelines. BMC Pulm Med. 2006 Nov 30;6 Suppl 1:S6. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877954"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "20692026", 
            "citation": "Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N, Chisholm A, Hillyer EV, Kemp L, Lee AJ, von Ziegenweidt J, Colice G. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol. 2010 Sep;126(3):511-8.e1-10. Epub 2010 Aug 9."
        }, 
        "secondary_outcome": [
            {
                "description": "Risk domain asthma control as defined above, plus\n(a)Average prescribed daily dose of albuterol or terbutaline of \u2264200mg", 
                "measure": "Overall asthma control", 
                "safety_issue": "No", 
                "time_frame": "One year outcome period"
            }, 
            {
                "description": "Asthma-related hospitalisations\nDefinite: Hospitalisations coded with an asthma read code\nDefinite and probable: Hospitalisations with an asthma read code and uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of an asthma read code\nRespiratory hospitalisations\nDefinite: Hospitalisations coded with a lower respiratory code\nDefinite and probable: Hospitalisations with a lower respiratory read code  and uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of a lower respiratory read code", 
                "measure": "Hospitalisation rates", 
                "safety_issue": "No", 
                "time_frame": "One year outcome period"
            }, 
            {
                "description": "Asthma control and no change in therapy", 
                "measure": "Treatment success", 
                "safety_issue": "No", 
                "time_frame": "One year outcome period"
            }, 
            {
                "description": "Categorised as: <50%, 50-<70%, 70-<100%, \u2265100%.", 
                "measure": "Adherence to ICS therapy", 
                "safety_issue": "No", 
                "time_frame": "One year outcome period"
            }, 
            {
                "measure": "Use of short-acting beta2-agonist (\"reliever\") therapy", 
                "safety_issue": "No", 
                "time_frame": "One year outcome period"
            }
        ], 
        "source": "Research in Real-Life Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Research in Real-Life Ltd", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}